Literature DB >> 11314045

Control of cell cycle progression in human mesothelioma cells treated with gamma interferon.

C Vivo1, F Lévy, Y Pilatte, J Fleury-Feith, P Chrétien, I Monnet, L Kheuang, M C Jaurand.   

Abstract

Recombinant human interferon gamma (r-hu-IFNgamma) exerts both antitumoral activity in the early stages of human malignant mesothelioma and a cytostatic effect in human mesothelioma (HM) cell lines in vitro. The antiproliferative effect of interferons (IFNs) reported in a variety of cells has been attributed to several mechanisms. In order to progress in the understanding of HM cell growth modulation by r-hu-IFNgamma, modifications of cell cycle progression and expression of key cell cycle regulator proteins in response to r-hu-IFNgamma were examined. Nine HM cell lines were studied, including one resistant to the antiproliferative effect of r-hu-IFNgamma. Except in the resistant cell line r-hu-IFNgamma produced an arrest in the G1 and G2-M phases of the cell cycle, associated with a reduction in both cyclin A and cyclin dependent kinase inhibitors (CDKIs) expression. Moreover cyclin B1/cdc2 activity was decreased. The present study provides the first evidence of a G2-arrest in r-hu-IFNgamma-treated HM cell lines and indicates that HM cell lines, despite their tumorigenic origin still support cell cycle control. The cell cycle arrest induced by r-hu-IFNgamma seems to depend on cyclin regulation through p21(WAF1/CIP1)- and p27(Kip1)-independent mechanisms and is not directly related to the induced DNA damage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314045     DOI: 10.1038/sj.onc.1204199

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance.

Authors:  Xuefang Cao; Karen Leonard; Lynne I Collins; Sheng F Cai; Joshua C Mayer; Jacqueline E Payton; Michael J Walter; David Piwnica-Worms; Robert D Schreiber; Timothy J Ley
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 2.  IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review.

Authors:  Vasiliki Galani; Michalis Kastamoulas; Anna Varouktsi; Evangeli Lampri; Antigoni Mitselou; Dimitrios L Arvanitis
Journal:  Clin Exp Med       Date:  2016-07-14       Impact factor: 3.984

3.  Mechanisms of resistance to interferon-gamma-mediated cell growth arrest in human oral squamous carcinoma cells.

Authors:  Miki Hiroi; Kazumasa Mori; Keisuke Sekine; Yoshiichi Sakaeda; Jun Shimada; Yoshihiro Ohmori
Journal:  J Biol Chem       Date:  2009-07-13       Impact factor: 5.157

4.  Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis.

Authors:  Solange Romagnoli; Ester Fasoli; Valentina Vaira; Monica Falleni; Caterina Pellegrini; Anna Catania; Massimo Roncalli; Antonio Marchetti; Luigi Santambrogio; Guido Coggi; Silvano Bosari
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

5.  Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.

Authors:  Oluf Dimitri Røe; Endre Anderssen; Eli Helge; Caroline Hild Pettersen; Karina Standahl Olsen; Helmut Sandeck; Rune Haaverstad; Steinar Lundgren; Erik Larsson
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

6.  BMP and activin membrane-bound inhibitor regulate connective tissue growth factor controlling mesothelioma cell proliferation.

Authors:  Nguyen Truong Duc Hoang; Ghmkin Hassan; Tomoya Suehiro; Yuichi Mine; Tohru Matsuki; Makiko Fujii
Journal:  BMC Cancer       Date:  2022-09-15       Impact factor: 4.638

7.  Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation.

Authors:  C Vivo; C Lecomte; F Levy; K Leroy; Y Kirova; A Renier; L Kheuang; P Piedbois; D Chopin; M C Jaurand
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.